Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes
Source: Genome Web, February 2025
NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).
